46.32
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics Surges to 488th in Daily Rankings with 2.35 Billion Trading Volume Despite Slight Price Decline - AInvest
8,196 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Edgestream Partners L.P. - MarketBeat
Huntington's Disease Clinical, Companies, Therapeutic - openPR.com
What analysts say about PTC Therapeutics Inc. stockPhenomenal wealth increase - jammulinksnews.com
PTC Therapeutics Inc. Stock Analysis and ForecastDouble or triple returns - jammulinksnews.com
Is PTC Therapeutics Inc. a good long term investmentExceptional market positioning - jammulinksnews.com
What drives PTC Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Cwm LLC Buys 14,139 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results - Kilgore News Herald
Pega to Announce Financial Results for the Second Quarter of 2025 and Host Conference Call and Webcast - Yahoo.co
Pierre Gravier Sells 2,516 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
William Blair Predicts Weaker Earnings for PTC Therapeutics - MarketBeat
William Blair Forecasts Lower Earnings for PTC Therapeutics - MarketBeat
What makes PTC Therapeutics Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru
PTC Therapeutics Advances PKU Treatment with Sepiapterin Study - TipRanks
PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors - TipRanks
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance - GlobeNewswire Inc.
PTC Therapeutics stock gets Buy rating from UBS ahead of FDA decision - Investing.com Canada
Allspring Global Investments Holdings LLC Acquires Shares of 10,287 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Banque Pictet & Cie SA Acquires New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
PTC Therapeutics: Regulatory Catalysts and Financial Fortitude Position the Company for a Breakout Year - AInvest
Cantor Fitzgerald Has Negative View of PTCT FY2026 Earnings - MarketBeat
PTCT FY2025 EPS Forecast Decreased by Cantor Fitzgerald - MarketBeat
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation - Seeking Alpha
PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - inkl
EC approves PTC Thera’s Sephience for PKU - The Pharma Letter
Germany will be first launch for PTC's phenylketonuria drug - pharmaphorum
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - PR Newswire
PTC Therapeutics upgraded at BofA on FDA review for Friedreich's ataxia drug - MSN
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches - Yahoo Finance
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Company Announcement - Financial Times
10 Biotech Stocks Screaming a Buy - Insider Monkey
PTC Therapeutics (PTCT): Truist Securities Initiates Coverage with 'Buy' Rating | PTCT Stock News - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):